[HTML][HTML] Genomic characterization of functional high-risk multiple myeloma patients
Multiple myeloma (MM) patients with suboptimal response to induction therapy or early
relapse, classified as the functional high-risk (FHR) patients, have been shown to have poor …
relapse, classified as the functional high-risk (FHR) patients, have been shown to have poor …
Cutting-edge strategies and critical advancements in characterization and quantification of metabolites concerning translational metabolomics
Despite remarkable progress in drug discovery strategies, significant challenges are still
remaining in translating new insights into clinical applications. Scientists are devising …
remaining in translating new insights into clinical applications. Scientists are devising …
[HTML][HTML] Future in the Past: Azorella glabra Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells
Multiple myeloma (MM) is the second most common hematologic malignancy and, although
the development of novel agents has improved survival of patients, to date, it remains …
the development of novel agents has improved survival of patients, to date, it remains …
Histone deacetylase inhibitor LMK-235-mediated HO-1 expression induces apoptosis in multiple myeloma cells via the JNK/AP-1 signaling pathway
X Li, Y Guo, X Kuang, L Zhao, H Li, B Cheng, W Wang… - Life sciences, 2019 - Elsevier
Abstract Aims Histone deacetylase inhibitors (HDACis) are promising anticancer drugs that
open new areas of epigenetic drug discovery. Multiple myeloma (MM) is a malignant tumor …
open new areas of epigenetic drug discovery. Multiple myeloma (MM) is a malignant tumor …
[HTML][HTML] LRP1B polymorphisms are associated with multiple myeloma risk in a Chinese Han population
B Li, C Liu, G Cheng, M Peng, X Qin, Y Liu, Y Li… - Journal of …, 2019 - ncbi.nlm.nih.gov
Multiple myeloma (MM) is an extremely complex plasma cell malignancy that is genetically
heterogeneous. A recent Genome-wide association study (GWAS) indicated that variation at …
heterogeneous. A recent Genome-wide association study (GWAS) indicated that variation at …
[HTML][HTML] Association between interleukin gene polymorphisms and multiple myeloma susceptibility
MN Shahzad, I Ijaz, SSZH Naqvi… - Molecular and …, 2020 - spandidos-publications.com
The present study performed a retrospective observational study in order to investigate the
relationship between the interleukin family gene polymorphisms and risk of multiple …
relationship between the interleukin family gene polymorphisms and risk of multiple …
[PDF][PDF] Is it only osteoporosis? An endocrine perspective on a case of multiple myeloma
LA VALEA, A GHEMIGIAN - academia.edu
Introduction. Multiple myeloma represents a malignant skeleton condition, been considered
the most frequent bone malignancy of primary type in people older than 70 years. Myeloma …
the most frequent bone malignancy of primary type in people older than 70 years. Myeloma …
[PDF][PDF] Central Nervous System Myelomatosis in the Era of Precision Medicine
N Wick, M Chen - Hematopathology, 2019 - journals.librarypublishing.arizona …
Multiple myeloma (MM) is a diverse clonal plasma cell malignancy with resultant organ
damage including renal and bone marrow effects, as well as neurologic and immune …
damage including renal and bone marrow effects, as well as neurologic and immune …
AK-968 efficiently inhibits proliferation and induces cell apoptosis in human multiple myeloma cells
Y Dai, Y Xu, Y Jiang, W Jiang, X Liu… - Die Pharmazie-An …, 2019 - ingentaconnect.com
AK-968 is a small molecular weight compound. In this study, we evaluated its anti-tumor
effects on human multiple myeloma (MM) cells. Our results demonstrated that AK-968 …
effects on human multiple myeloma (MM) cells. Our results demonstrated that AK-968 …